Latest Peripheral vascular disease Stories
LAKEWOOD, Colo., July 28, 2011 /PRNewswire-USNewswire/ -- The Vascular Disease Foundation (VDF) is pleased to announce that Thomas R.
MINNEAPOLIS, July 25, 2011 /PRNewswire/ -- Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy(TM) Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD).
As the population ages and obesity and diabetes increase, more people suffer from noncardiac vascular diseases.
MINNEAPOLIS, June 28, 2011 /PRNewswire/ -- Lutonix today announced receiving approval from the US Food and Drug Administration to begin enrollment in its LEVANT 2 IDE clinical trial for the treatment of peripheral arterial disease (PAD), along with receipt of CE Mark for its drug-coated balloon and ISO certification.
Millions of adults with peripheral artery disease (PAD) are not receiving the medications needed to reduce their risk of heart attack, stroke and death, according to this study.
Millions of adults with peripheral artery disease are not receiving the medications needed to reduce their risk of heart attack, stroke and death.
Outcomes of bypass surgery to repair blocked arteries in the legs tend to be better in the roughly one-in-five people who have inherited a specific genetic variation from both parents.
NATICK, Mass., June 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Mustang(TM) PTA Balloon Catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures.
MONTREAL, June 13, 2011 /PRNewswire/ -- Researchers today announced the results of a study that show echocardiography can improve the success rate of gene therapy and increase growth, function and sustainability of regenerated vessels.
SAN DIEGO, May 4, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), the leading developer and manufacturer of precision guided therapy tools designed to enhance the treatment of coronary and peripheral vascular disease, today announced the signing of a supply agreement with ev3, a Covidien company, under which Volcano will supply its proprietary Intravascular Ultrasound (IVUS) technology for use in ev3's Plaque Excision Systems.
- The act of sweetening by admixture of some saccharine substance.